Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 131

1.

Multimeric soluble CD40 ligand and GITR ligand as adjuvants for human immunodeficiency virus DNA vaccines.

Stone GW, Barzee S, Snarsky V, Kee K, Spina CA, Yu XF, Kornbluth RS.

J Virol. 2006 Feb;80(4):1762-72.

2.

Soluble multi-trimeric TNF superfamily ligand adjuvants enhance immune responses to a HIV-1 Gag DNA vaccine.

Kanagavelu SK, Snarsky V, Termini JM, Gupta S, Barzee S, Wright JA, Khan WN, Kornbluth RS, Stone GW.

Vaccine. 2012 Jan 17;30(4):691-702. doi: 10.1016/j.vaccine.2011.11.088. Epub 2011 Dec 4.

3.

Vaccination with a fusion protein that introduces HIV-1 gag antigen into a multitrimer CD40L construct results in enhanced CD8+ T cell responses and protection from viral challenge by vaccinia-gag.

Gupta S, Termini JM, Raffa FN, Williams CA, Kornbluth RS, Stone GW.

J Virol. 2014 Feb;88(3):1492-501. doi: 10.1128/JVI.02229-13. Epub 2013 Nov 13.

4.

Macaque multimeric soluble CD40 ligand and GITR ligand constructs are immunostimulatory molecules in vitro.

Stone GW, Barzee S, Snarsky V, Spina CA, Lifson JD, Pillai VK, Amara RR, Villinger F, Kornbluth RS.

Clin Vaccine Immunol. 2006 Nov;13(11):1223-30. Epub 2006 Sep 20.

5.

HIV-1 adenoviral vector vaccines expressing multi-trimeric BAFF and 4-1BBL enhance T cell mediated anti-viral immunity.

Kanagavelu S, Termini JM, Gupta S, Raffa FN, Fuller KA, Rivas Y, Philip S, Kornbluth RS, Stone GW.

PLoS One. 2014 Feb 28;9(2):e90100. doi: 10.1371/journal.pone.0090100. eCollection 2014.

7.

The adjuvancy of OX40 ligand (CD252) on an HIV-1 canarypox vaccine.

Liu J, Ngai N, Stone GW, Yue FY, Ostrowski MA.

Vaccine. 2009 Aug 13;27(37):5077-84. doi: 10.1016/j.vaccine.2009.06.046. Epub 2009 Jun 30.

PMID:
19573639
8.

A multi-trimeric fusion of CD40L and gp100 tumor antigen activates dendritic cells and enhances survival in a B16-F10 melanoma DNA vaccine model.

Gupta S, Termini JM, Rivas Y, Otero M, Raffa FN, Bhat V, Farooq A, Stone GW.

Vaccine. 2015 Sep 11;33(38):4798-806. doi: 10.1016/j.vaccine.2015.07.081. Epub 2015 Aug 1.

9.

CD40L-adjuvanted DNA/modified vaccinia virus Ankara simian immunodeficiency virus SIV239 vaccine enhances SIV-specific humoral and cellular immunity and improves protection against a heterologous SIVE660 mucosal challenge.

Kwa S, Lai L, Gangadhara S, Siddiqui M, Pillai VB, Labranche C, Yu T, Moss B, Montefiori DC, Robinson HL, Kozlowski PA, Amara RR.

J Virol. 2014 Sep 1;88(17):9579-89. doi: 10.1128/JVI.00975-14. Epub 2014 Jun 11.

10.

Trimer stabilization, oligomerization, and antibody-mediated cell surface immobilization improve the activity of soluble trimers of CD27L, CD40L, 41BBL, and glucocorticoid-induced TNF receptor ligand.

Wyzgol A, Müller N, Fick A, Munkel S, Grigoleit GU, Pfizenmaier K, Wajant H.

J Immunol. 2009 Aug 1;183(3):1851-61. doi: 10.4049/jimmunol.0802597. Epub 2009 Jul 13.

11.

A stabilized HIV-1 envelope glycoprotein trimer fused to CD40 ligand targets and activates dendritic cells.

Melchers M, Matthews K, de Vries RP, Eggink D, van Montfort T, Bontjer I, van de Sandt C, David K, Berkhout B, Moore JP, Sanders RW.

Retrovirology. 2011 Jun 20;8:48. doi: 10.1186/1742-4690-8-48.

12.
13.

Cytotoxic T lymphocyte and helper T cell responses following HIV polynucleotide vaccination.

Shiver JW, Perry HC, Davies ME, Freed DC, Liu MA.

Ann N Y Acad Sci. 1995 Nov 27;772:198-208.

PMID:
8546393
14.

Design, construction, and characterization of a dual-promoter multigenic DNA vaccine directed against an HIV-1 subtype C/B' recombinant.

Huang Y, Chen Z, Zhang W, Gurner D, Song Y, Gardiner DF, Ho DD.

J Acquir Immune Defic Syndr. 2008 Apr 1;47(4):403-11. doi: 10.1097/QAI.0b013e3181651b9d.

PMID:
18209683
15.

Enhancement of the priming efficacy of DNA vaccines encoding dendritic cell-targeted antigens by synergistic toll-like receptor ligands.

Grossmann C, Tenbusch M, Nchinda G, Temchura V, Nabi G, Stone GW, Kornbluth RS, Uberla K.

BMC Immunol. 2009 Aug 3;10:43. doi: 10.1186/1471-2172-10-43.

16.

DNA vaccine molecular adjuvants SP-D-BAFF and SP-D-APRIL enhance anti-gp120 immune response and increase HIV-1 neutralizing antibody titers.

Gupta S, Clark ES, Termini JM, Boucher J, Kanagavelu S, LeBranche CC, Abraham S, Montefiori DC, Khan WN, Stone GW.

J Virol. 2015 Apr;89(8):4158-69. doi: 10.1128/JVI.02904-14. Epub 2015 Jan 28.

17.
18.

Cutting edge: a potent adjuvant effect of ligand to receptor activator of NF-kappa B gene for inducing antigen-specific CD8+ T cell response by DNA and viral vector vaccination.

Miyahira Y, Akiba H, Katae M, Kubota K, Kobayashi S, Takeuchi T, García-Sastre A, Fukuchi Y, Okumura K, Yagita H, Aoki T.

J Immunol. 2003 Dec 15;171(12):6344-8.

19.

Mucosal and systemic HIV-1 Env-specific CD8(+) T-cells develop after intragastric vaccination with a Salmonella Env DNA vaccine vector.

Shata MT, Reitz MS Jr, DeVico AL, Lewis GK, Hone DM.

Vaccine. 2001 Nov 12;20(3-4):623-9.

PMID:
11672930
20.

Supplemental Content

Support Center